<DOC>
	<DOCNO>NCT02649998</DOCNO>
	<brief_summary>Background : Acute decompensated heart failure ( ADHF ) common potentially fatal cause acute respiratory distress require immediate treatment emergency department . The mortality rate high 20 % discharge . Currently , furosemide commonly used medicine emergency department ADHF . Although nitrate prove generate similar effect compare furosemide , less 30 % patient receive nitrate . This practice happen Hong Kong , also around world . Moreover , limit evidence support difference ADHF patient receive intravenous nitrate vasodilator therapy alternative intervention . The aim study : 1 . To monitor change concentration cardiac biomarkers , VAS dyspnoea score cardiac output treatment furosemide , isosorbide dinitrate . 2 . To investigate whether change concentration cardiac biomarkers , VAS dyspnoea score cardiac output treatment associate change length hospital stay . 3 . To investigate whether combination treatment intravenous furosemide isosorbide dinitrate patient HF reduce VAS dyspnoea score , in-hospital mortality , length hospital stay number readmission high extend either medication alone . 4 . To evaluate prognostic value novel cardiac biomarkers 7-day , 14-day , 30-day 6-month mortality readmission . Design : This single-blinded randomized control study conduct Prince Wales Hospital Hong Kong . Setting Subjects : Patients dyspnoea screen recruited adult patient attend emergency department Prince Wales Hospital . Interventions : Patients acute decompensated heart failure randomly treat intravenous furosemide , isosorbide dinitrate . Level dyspnoea , multi-biomarker haemodynamic parameter measure treatment . Outcomes : The primary outcome change VAS dyspnoea score treatment furosemide , isosorbide dinitrate . The secondary outcome change concentration biomarkers cardiac output , number in-hospital mortality , length hospital stay , 7-day 30-day 6-month mortality readmission .</brief_summary>
	<brief_title>Short-term Efficacy Furosemide , Isosorbide Dinitrate Their Combination ADHF</brief_title>
	<detailed_description>Definitions : Heart failure define abnormality cardiac structure function leading failure heart deliver oxygen rate commensurate requirement metabolize tissue , despite normal filling pressure ( expense increase filling pressure ) . Acute decompensated Heart Failure ( ADHF ) , define accord Framingham criterion change symptom sign context heart failure . For study define acute change symptom sign within previous 24 hour . In New York Heart Association classification ( NYHA ) , Class I : limitation experience activity ; symptom ordinary activity . ; Class II : slight , mild limitation activity ; patient comfortable rest mild exertion . ; Class III : marked limitation activity ; patient comfortable rest . ; Class IV : physical activity bring discomfort symptom occur rest .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<criteria>Patients age 18 year old increase dyspnoea within previous 24 hour Diagnosed heart failure physician Women know suspected pregnancy ; myocardial infarction cardiac surgery within previous three month ; Oxygen saturation le 85 % room air ; Respiratory rate great 30 breaths/min ; pH &lt; 7.35 ; systolic blood pressure &lt; 110 bpm ; Current treatment oral nitrate excess 40 mg daily ; Current treatment oral furosemide excess 80 mg daily ; Previous adverse reaction study drug ; Requirement noninvasive ventilation ; Severe renal failure ( creatinine &gt; 200 Âµmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Fursemide</keyword>
	<keyword>Isosorbide Dinitrate</keyword>
	<keyword>Heart Decompensation</keyword>
	<keyword>Clinical Trials , Randomized</keyword>
	<keyword>Clinical Efficacy</keyword>
</DOC>